Iteos Gross Profit from 2010 to 2025

ITOS Stock

USD 7.07 0.09 1.29%

Iteos Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit will likely drop to about 12.8 M in 2025. Gross Profit is the profit Iteos Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

13.5 M

Current Value

12.8 M

Quarterly Volatility

104.7 M

Credit Downgrade

Yuan Drop

Covid

Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 3.9 M, Net Interest Income of 37.3 M or Interest Income of 37.3 M, as well as many indicators such as Price To Sales Ratio of 29.38, Dividend Yield of 0.0 or PTB Ratio of 0.74. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.

Check out the analysis of Iteos Therapeutics Correlation against competitors.

For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.

Latest Iteos Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Iteos Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Iteos Therapeutics minus its cost of goods sold. It is profit before Iteos Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Iteos Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iteos Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 35 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Iteos Gross Profit Regression Statistics

	Arithmetic Mean	40,141,220
	Coefficient Of Variation	260.76
	Mean Deviation	66,336,820
	Median	(611,000)
	Standard Deviation	104,671,366
	Sample Variance	10956.1T
	Range	344.8M
	R-Value	0.36
	Mean Square Error	10241.2T
	R-Squared	0.13
	Significance	0.17
	Slope	7,852,470
	Total Sum of Squares	164341.4T

Iteos Gross Profit History

	2025	12.8 M
	2024	13.5 M
	2023	11.7 M
	2022	266.8 M
	2021	344.2 M
	2020	-535 K

Other Fundumenentals of Iteos Therapeutics

Gross Profit Margin

Iteos Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		0.98	0.94	0.53	-0.83	0.87	0.81	0.77	0.86	0.82	0.98	0.99	-0.86	0.99	-0.53	-0.68	0.96
Total Stockholder Equity	0.98		0.96	0.37	-0.74	0.86	0.85	0.68	0.87	0.7	1.0	0.96	-0.87	1.0	-0.55	-0.69	0.97
Net Tangible Assets	0.94	0.96		0.28	-0.67	0.87	0.95	0.66	0.84	0.66	0.95	0.92	-0.88	0.95	-0.55	-0.68	0.93
Current Deferred Revenue	0.53	0.37	0.28		-0.86	0.34	0.07	0.73	0.31	0.9	0.37	0.6	-0.33	0.44	-0.16	-0.26	0.37
Net Debt	-0.83	-0.74	-0.67	-0.86		-0.57	-0.44	-0.77	-0.67	-0.94	-0.74	-0.88	0.71	-0.79	0.4	0.55	-0.67
Retained Earnings	0.87	0.86	0.87	0.34	-0.57		0.81	0.62	0.65	0.67	0.86	0.83	-0.71	0.85	-0.45	-0.49	0.88
Accounts Payable	0.81	0.85	0.95	0.07	-0.44	0.81		0.59	0.74	0.49	0.84	0.77	-0.77	0.83	-0.5	-0.61	0.87
Net Receivables	0.77	0.68	0.66	0.73	-0.77	0.62	0.59		0.71	0.89	0.67	0.8	-0.44	0.71	-0.13	-0.67	0.77
Capital Surpluse	0.86	0.87	0.84	0.31	-0.67	0.65	0.74	0.71		0.6	0.87	0.84	-0.62	0.87	-0.14	-0.95	0.87
Total Liab	0.82	0.7	0.66	0.9	-0.94	0.67	0.49	0.89	0.6		0.7	0.86	-0.61	0.75	-0.35	-0.49	0.72
Net Invested Capital	0.98	1.0	0.95	0.37	-0.74	0.86	0.84	0.67	0.87	0.7		0.96	-0.88	1.0	-0.57	-0.67	0.96
Total Current Assets	0.99	0.96	0.92	0.6	-0.88	0.83	0.77	0.8	0.84	0.86	0.96		-0.85	0.98	-0.52	-0.67	0.93
Capital Stock	-0.86	-0.87	-0.88	-0.33	0.71	-0.71	-0.77	-0.44	-0.62	-0.61	-0.88	-0.85		-0.88	0.83	0.38	-0.76
Net Working Capital	0.99	1.0	0.95	0.44	-0.79	0.85	0.83	0.71	0.87	0.75	1.0	0.98	-0.88		-0.55	-0.69	0.96
Short Term Debt	-0.53	-0.55	-0.55	-0.16	0.4	-0.45	-0.5	-0.13	-0.14	-0.35	-0.57	-0.52	0.83	-0.55		-0.16	-0.46
Common Stock	-0.68	-0.69	-0.68	-0.26	0.55	-0.49	-0.61	-0.67	-0.95	-0.49	-0.67	-0.67	0.38	-0.69	-0.16		-0.7
Property Plant Equipment	0.96	0.97	0.93	0.37	-0.67	0.88	0.87	0.77	0.87	0.72	0.96	0.93	-0.76	0.96	-0.46	-0.7

Click cells to compare fundamentals

About Iteos Therapeutics Financial Statements

Iteos Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	13.5 M	12.8 M
Gross Profit Margin	0.93	1.07

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Iteos Stock Analysis

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC